NMS·Healthcare·$1.3B·#277 / 520 in Healthcare

LMRI Lumexa Imaging Holdings, Inc.

39HIGH RISK

CATEGORY BREAKDOWN

GROWTH2
QUALITY16
STABILITY83
VALUATION50
GOVERNANCE33

METRIC BREAKDOWN

Revenue Growth (YoY)

Year-over-year revenue growth rate

+1.4%
2

> 50% strong

Gross Margin

Revenue retained after direct costs

10.1%
14

> 50% strong

Cash Runway

Months of cash at current burn rate

999 months
100

> 24 months ideal

Debt / Equity

Total debt relative to shareholder equity

N/A
50

< 25% strong

Price / Sales

Market cap relative to trailing revenue

N/A
50

< 3x strong

Rule of 40

Growth rate plus operating margin

-0
20

> 40 excellent

Insider Ownership

Percentage of shares held by insiders

N/A
0

> 20% strong

Share Dilution (12M)

Share count increase over last 12 months

+0.0%
100

< 5% ideal

5 more metrics available

Unlock all 8 metrics, score history, watchlist, and side-by-side comparison.

Try Free for 30 Days

AI ANALYSIS REPORT

AI-GENERATED

BUSINESS SUMMARY

Lumexa Imaging Holdings, Inc. (LMRI) is a healthcare company trading on NMS with a market capitalization of $1.3B. The company currently carries a HIGH RISK rating of 39/100, flagging significant fundamental concerns. The fundamental profile shows modest single-digit revenue growth at 1.4% year-over-year, paired with thin gross margins that leave little room for error at 10.1%. The balance sheet shows unavailable debt data, and the company has effectively infinite cash runway, indicating operational self-sufficiency.

VERDICT

LMRI scores 39/100 — the fundamentals flag multiple areas of concern. Only suitable for investors with high risk tolerance and a specific catalyst thesis. This report is based on the latest available financial data and is intended as a starting point for research, not a buy or sell recommendation.

MARKET OPPORTUNITY

In the healthcare sector, cash runway and pipeline progress are critical metrics. Revenue quality depends on whether income comes from product sales, partnerships, or milestones. Lumexa Imaging Holdings, Inc. operates with unknown insider ownership, which provides a signal about management's confidence in the company's direction. At a market cap of $1.3B, the company is unavailable valuation data at N/A P/S. The combination of these factors positions LMRI as a higher-risk position that requires careful due diligence before considering an investment.

REVENUE QUALITY

Revenue growth stands at 1.4% year-over-year, which is in line with the typical small-cap growth rate. Gross margins of 10.1% are thin and may compress further under competitive pressure. The Rule of 40 score of 0 is well below the benchmark, indicating challenges in both growth and profitability. Cash runway is effectively infinite, meaning the company generates enough cash to sustain operations without external funding.

COMPETITIVE ADVANTAGE

Evaluating Lumexa Imaging Holdings, Inc.'s competitive position requires looking beyond the numbers. Insider ownership at N/A is relatively low, which may indicate that management's interests are less aligned with shareholders. The margin structure suggests the company operates in a competitive market where differentiation is harder to maintain. Share count management has been reasonable. Investors should research the specific sources of competitive advantage — patents, customer switching costs, scale economies, or brand — that could protect margins over time.

GROWTH THESIS

LMRI presents a speculative fundamental profile that requires a specific thesis to justify investment. The low N/A P/S ratio could represent value if the company can stabilize or accelerate its growth. Key catalysts to watch include: revenue growth trajectory over the next 2-3 quarters, margin expansion or contraction, and any changes in insider buying or selling activity.

KEY RISKS

Execution risk is significant — many small-cap companies in this sector fail to transition from growth to profitability. Thin gross margins leave little buffer against cost increases or competitive pricing pressure. Small-cap stocks carry inherently higher risk than large-caps, including limited analyst coverage, lower institutional ownership, and higher sensitivity to market downturns. Always conduct thorough due diligence beyond quantitative metrics.

Full AI Report available

Unlock the complete analysis including market opportunity, revenue quality, competitive moat, growth thesis, and risk assessment.

Try Free for 30 Days

Report generated: Mar 26, 2026

SCORE HISTORY

Track how this score changes over time. Start your free trial to see the full score trend chart.

SCORE ALERT

Get notified when LMRI's score changes by 5+ points.

DATA INFO

Last updated: Mar 11, 2026

Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.